Movement Disorders and SARS‐CoV ‐2
2022; Wiley; Volume: 10; Issue: S2 Linguagem: Holandês
10.1002/mdc3.13615
ISSN2330-1619
AutoresWilson Fung, Alfonso Fasano, Conor Fearon,
Tópico(s)Restless Legs Syndrome Research
ResumoMovement Disorders Clinical PracticeVolume 10, Issue S2 p. S9-S17 VIEWPOINT Movement Disorders and SARS-CoV-2 Wilson K.W. Fung MD, Wilson K.W. Fung MD Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorAlfonso Fasano MD, PhD, Corresponding Author Alfonso Fasano MD, PhD [email protected] orcid.org/0000-0001-5346-0180 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, Canada Krembil Research Institute, Toronto, Ontario, Canada Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada Department of Parkinson's Disease and Movement Disorders Rehabilitation, 'Moriggia-Pelascini' Hospital – Gravedona ed Uniti, Como, Italy Correspondence to: Prof. Alfonso Fasano, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, 7McL410, Toronto, Ontario, M5T 2S8 Canada; E-mail: [email protected]Search for more papers by this authorConor Fearon MB, PhD, Conor Fearon MB, PhD orcid.org/0000-0002-8172-6094 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author Wilson K.W. Fung MD, Wilson K.W. Fung MD Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this authorAlfonso Fasano MD, PhD, Corresponding Author Alfonso Fasano MD, PhD [email protected] orcid.org/0000-0001-5346-0180 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, Canada Krembil Research Institute, Toronto, Ontario, Canada Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, Ontario, Canada Department of Parkinson's Disease and Movement Disorders Rehabilitation, 'Moriggia-Pelascini' Hospital – Gravedona ed Uniti, Como, Italy Correspondence to: Prof. Alfonso Fasano, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, 399 Bathurst St, 7McL410, Toronto, Ontario, M5T 2S8 Canada; E-mail: [email protected]Search for more papers by this authorConor Fearon MB, PhD, Conor Fearon MB, PhD orcid.org/0000-0002-8172-6094 Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital – UHN, University of Toronto, Toronto, Ontario, CanadaSearch for more papers by this author First published: 14 November 2022 https://doi.org/10.1002/mdc3.13615Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Fearon C, Fasano A. Parkinson's disease and the COVID-19 pandemic. J Parkinsons Dis 2021; 11(2): 431–444. 10.3233/JPD-202320 CASPubMedWeb of Science®Google Scholar 2Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 2022; 29(4): 1243–1253. 10.1111/ene.15217 PubMedWeb of Science®Google Scholar 3Delgado C, Pareés I, Kurtis MM. Patients' perspective of dystonia symptoms during the SARS-CoV-2 pandemic. Mov Disord. Published online May 11, 2021;36(7):1485–1486. https://doi.org/10.1002/mds.28645. 10.1002/mds.28645 Web of Science®Google Scholar 4Conte G, Baglioni V, Valente F, Chiarotti F, Cardona F. Adverse mental health impact of the COVID-19 lockdown in individuals with Tourette syndrome in Italy: An online survey. Front Psych 2020; 11:583744. 10.3389/fpsyt.2020.583744 Web of Science®Google Scholar 5Mataix-Cols D, Ringberg H, Fernández de la Cruz L. Perceived worsening of tics in adult patients with Tourette syndrome after the COVID-19 outbreak. Mov Disord Clin Pract. 2020; 7(6): 725–726. 10.1002/mdc3.13004 PubMedWeb of Science®Google Scholar 6Artusi CA, Romagnolo A, Imbalzano G, Marchet A, Zibetti M, Rizzone MG, Lopiano L. COVID-19 in Parkinson's disease: Report on prevalence and outcome. Parkinsonism Relat Disord 2020; 80: 7–9. 10.1016/j.parkreldis.2020.09.008 PubMedWeb of Science®Google Scholar 7Salari M, Etemadifar M, Zali A, Medghalchi A, Tehrani Fateh S, Aminzade Z, Bagheri Moghaddam S. Seroprevalence of SARS-CoV-2 in Parkinson's disease patients: A case-control study. Mov Disord 2021; 36(4): 794–795. 10.1002/mds.28580 CASPubMedWeb of Science®Google Scholar 8Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, De la Cruz-Ku GA, Custodio N. Factors associated with COVID-19 in people with Parkinson's disease: A systematic review and meta-analysis. Eur J Neurol 2021; 28(10): 3467–3477. 10.1111/ene.14912 PubMedWeb of Science®Google Scholar 9El-Qushayri AE, Ghozy S, Reda A, Kamel AMA, Abbas AS, Dmytriw AA. The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: a systematic review and meta-analysis. Rev Med Virol 2021; 32:e2278. PubMedWeb of Science®Google Scholar 10Khoshnood RJ, Zali A, Tafreshinejad A, Ghajarzadeh M, Ebrahimi N, Safari S, Mirmosayyeb O. Parkinson's disease and COVID-19: A systematic review and meta-analysis. Neurol Sci 2021;43(2):775-783.. https://doi.org/10.1007/s10072-021-05756-4. 10.1007/s10072-021-05756-4 PubMedWeb of Science®Google Scholar 11Artusi CA, Romagnolo A, Ledda C, et al. COVID-19 and Parkinson's disease: What do we know so far? J Parkinsons Dis 2021; 11(2): 445–454. 10.3233/JPD-202463 CASPubMedWeb of Science®Google Scholar 12Kobylecki C, Jones T, Lim CK, Miller C, Thomson AM. Phenomenology and outcomes of In-patients with Parkinson's disease during the coronavirus disease 2019 pandemic. Mov Disord 2020; 35(8): 1295–1296. 10.1002/mds.28205 CASPubMedWeb of Science®Google Scholar 13Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism Relat Disord 2020; 75: 126–127. 10.1016/j.parkreldis.2020.05.008 PubMedWeb of Science®Google Scholar 14Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's disease patients affected by COVID-19. Mov Disord 2020; 35(6): 905–908. 10.1002/mds.28104 CASPubMedWeb of Science®Google Scholar 15Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of hospitalized Parkinson's disease patients with and without COVID-19. Mov Disord Clin Pract 2021;8(6): 859–867. 10.1002/mdc3.13231 PubMedWeb of Science®Google Scholar 16Salari M, Etemadifar M, Ashrafi F, Ommi D, Aminzade Z, Tehrani FS. Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran. Parkinsonism Relat Disord 2021; 89: 90–92. 10.1016/j.parkreldis.2021.07.002 CASPubMedWeb of Science®Google Scholar 17Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zecchinelli AL, Pezzoli G. COVID-19 in Parkinson's disease patients living in Lombardy. Italy Mov Disord 2020; 35: 1089–1093. 10.1002/mds.28176 CASPubMedWeb of Science®Google Scholar 18Leta V, Rodríguez-Violante M, Abundes A, et al. Parkinson's disease and post–COVID-19 syndrome: The Parkinson's long-COVID Spectrum. Mov Disord 2021; 36(6): 1287–1289. 10.1002/mds.28622 CASPubMedWeb of Science®Google Scholar 19Fabbri M, Leung C, Baille G, et al. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study. Parkinsonism Relat Disord 2021; 89: 128–133. 10.1016/j.parkreldis.2021.07.013 CASPubMedWeb of Science®Google Scholar 20Gultekin M, Tufekcioglu Z. COVID-19 infection presented as severe dyskinesia in a patient with Parkinson's disease: a case with daily video recording. Neurol Sci 2022; 43(5): 2961–2963. 10.1007/s10072-022-05912-4 PubMedWeb of Science®Google Scholar 21Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Mov Disord Off J Mov Disord Soc 2020; 35(7): 1097–1099. 10.1002/mds.28134 CASPubMedWeb of Science®Google Scholar 22Yule E, Pickering JS, McBride J, Poliakoff E. People with Parkinson's report increased impulse control behaviours during the COVID-19 UK lockdown. Parkinsonism Relat Disord 2021; 86: 38–39. 10.1016/j.parkreldis.2021.03.024 CASPubMedWeb of Science®Google Scholar 23Kumar N, Gupta R. Impact of COVID-19 pandemic on Parkinson's disease: A tale of fears and sorrows! Ann Indian Acad Neurol 2021; 24(2): 121–123. 10.4103/aian.AIAN_97_21 PubMedWeb of Science®Google Scholar 24Cheong JLY, Goh ZHK, Marras C, Tanner CM, Kasten M, Noyce AJ, the Movement Disorders Society Epidemiology Study Group. The impact of COVID-19 on access to Parkinson's disease medication. Mov Disord 2020; 35(12): 2129–2133. 10.1002/mds.28293 CASPubMedWeb of Science®Google Scholar 25van der Kolk NM, de Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B, Bloem BR. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: A double-blind, randomised controlled trial. Lancet Neurol 2019; 18(11): 998–1008. 10.1016/S1474-4422(19)30285-6 PubMedWeb of Science®Google Scholar 26Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: National prospective cohort study. BMJ 2021; 374:n2244. 10.1136/bmj.n2244 PubMedGoogle Scholar 27Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology 2020; 95(8): e1060–e1070. 10.1212/WNL.0000000000009937 CASPubMedWeb of Science®Google Scholar 28Xiong W, Mu J, Guo J, et al. New onset neurologic events in people with COVID-19 infection in three regions in China. Neurology 2020; 95: e1479–e1487. 10.1212/WNL.0000000000010034 CASPubMedWeb of Science®Google Scholar 29Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19: A systematic review and meta-analysis. Neurology 2021; 97(23): e2269–e2281. 10.1212/WNL.0000000000012930 CASPubMedWeb of Science®Google Scholar 30Brandão PRP, Grippe TC, Pereira DA, Munhoz RP, Cardoso F. New-onset movement disorders associated with COVID-19. Tremor Hyperkinetic Mov N Y N 2021; 11: 26. 10.5334/tohm.595 PubMedWeb of Science®Google Scholar 31Fung WKW, Sa'di Q, Katzberg H, et al. Functional Disorders as a Common Motor Manifestation of COVID-19 Infection or Vaccination [published online ahead of print, 2022 Nov 11]. Eur J Neurol. 2022; doi:10.1111/ene.15630. Google Scholar 32Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: A case report and systematic review. J Neurol 2021; 268(10): 3517–3548. 10.1007/s00415-021-10458-0 CASPubMedWeb of Science®Google Scholar 33Khoo A, McLoughlin B, Cheema S, et al. Postinfectious brainstem encephalitis associated with SARS-CoV-2. J Neurol Neurosurg Psychiatry 2020; 91: 1013–1014. 10.1136/jnnp-2020-323816 PubMedWeb of Science®Google Scholar 34Muccioli L, Rondelli F, Ferri L, Rossini G, Cortelli P, Guarino M. Subcortical myoclonus in COVID-19: Comprehensive evaluation of a patient. Mov Disord Clin Pract 2020; 7: 971–973. 10.1002/mdc3.13046 PubMedWeb of Science®Google Scholar 35Beretta S, Stabile A, Balducci C, et al. COVID-19-associated immune-mediated encephalitis mimicking acute-onset Creutzfeldt-Jakob disease. Ann Clin Transl Neurol 2021; 8(12): 2314–2318. 10.1002/acn3.51479 CASPubMedWeb of Science®Google Scholar 36Cunha P, Herlin B, Vassilev K, et al. Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection. Eur J Neurol 2020; 27: e88–e90. PubMedWeb of Science®Google Scholar 37Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, Mummery CJ, Bloem BR. Reversible myoclonus-ataxia as a Postinfectious manifestation of COVID-19. Mov Disord Clin Pract. 2020; 7(8): 977–979. 10.1002/mdc3.13088 PubMedWeb of Science®Google Scholar 38Fadakar N, Ghaemmaghami S, Masoompour SM, et al. A first case of acute Cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review. Cerebellum Lond Engl 2020;19(6):911–914. 10.1007/s12311-020-01177-9 PubMedWeb of Science®Google Scholar 39Sharma S, Ruparelia J, Bhaskar S, Tiwari S, Nag VL, Panda S. Acute fulminant Cerebellitis in children with COVID-19 infection: A rare but treatable complication. Pediatr Neurol 2021; 119: 45–47. 10.1016/j.pediatrneurol.2021.03.004 PubMedWeb of Science®Google Scholar 40Povlow A, Auerbach AJ. Acute cerebellar ataxia in COVID-19 infection: A case report. J Emerg Med 2021; 60(1): 73–76. 10.1016/j.jemermed.2020.10.010 PubMedWeb of Science®Google Scholar 41Li Z, Li X, Shen J, Chan MTV, Wu WKK. Miller fisher syndrome associated with COVID-19: An up-to-date systematic review. Environ Sci Pollut Res Int 2021; 28(17): 20939–20944. 10.1007/s11356-021-13233-w CASPubMedWeb of Science®Google Scholar 42Li X, Wang Y, Wang H, Wang Y. SARS-CoV-2-associated Guillain-Barré syndrome is a Para-infectious disease. QJM Int J Med 2021; 114: 625–635. 10.1093/qjmed/hcab157 CASWeb of Science®Google Scholar 43Mondal R, Deb S, Shome G, Ganguly U, Lahiri D, Benito-León J. COVID-19 and emerging spinal cord complications: A systematic review. Mult Scler Relat Disord 2021; 51:102917. 10.1016/j.msard.2021.102917 CASPubMedWeb of Science®Google Scholar 44Emekli AS, Parlak A, Göcen NY, Kürtüncü M. Anti-GAD associated post-infectious cerebellitis after COVID-19 infection. Neurol Sci 2021; 42(10): 3995–4002. 10.1007/s10072-021-05506-6 PubMedWeb of Science®Google Scholar 45Hayashi M, Sahashi Y, Baba Y, Okura H, Shimohata T. COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion. J Neurol Sci 2020; 415:116941. 10.1016/j.jns.2020.116941 CASPubMedWeb of Science®Google Scholar 46Nelson JL, Blume GM, Bansal SK, Kaufman JR, Woods FR, Zhang X, Kattah JC. Postinfectious SARS-CoV-2 Opsoclonus-myoclonus-ataxia syndrome. J Neuro-Ophthalmol 2021; 42: 251–255. 10.1097/WNO.0000000000001498 PubMedWeb of Science®Google Scholar 47Smyth D, Kyaw KM, Legister A, et al. Post-COVID-19 opsoclonus-myoclonus syndrome and encephalopathy associated with leucine-rich glioma-inactivated 1 (LGI-1) antibodies. J Neurol Sci 2021; 430:119982. 10.1016/j.jns.2021.119982 CASPubMedWeb of Science®Google Scholar 48Ishaq H, Durrani T, Umar Z, Khan N, McCombe P, Ul Haq MA. Post-COVID Opsoclonus myoclonus syndrome: A case report from Pakistan. Front Neurol 2021; 12:672524. 10.3389/fneur.2021.672524 PubMedWeb of Science®Google Scholar 49Saha B, Saha S, Chong WH. 78-year-old woman with opsoclonus myoclonus ataxia syndrome secondary to COVID-19. BMJ Case Rep 2021; 14(5):e243165. 10.1136/bcr-2021-243165 PubMedGoogle Scholar 50Fernandes J, Puhlmann P. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2. J Neurovirol 2021; 27(3): 501–503. 10.1007/s13365-021-00974-0 CASPubMedWeb of Science®Google Scholar 51Urrea-Mendoza E, Okafor K, Ravindran S, Absher J, Chaubal V, Revilla FJ. Opsoclonus-myoclonus-ataxia syndrome (OMAS) associated with SARS-CoV-2 infection: Post-infectious neurological complication with benign prognosis. Tremor Hyperkinetic Mov N Y N. 2021; 11: 7. 10.5334/tohm.580 PubMedWeb of Science®Google Scholar 52Foucard C, San-Galli A, Tarrano C, Chaumont H, Lannuzel A, Roze E. Acute cerebellar ataxia and myoclonus with or without opsoclonus: A Para-infectious syndrome associated with COVID-19. Eur J Neurol 2021; 28(10): 3533–3536. 10.1111/ene.14726 PubMedWeb of Science®Google Scholar 53Gold DM, Galetta SL. Neuro-ophthalmologic complications of coronavirus disease 2019 (COVID-19). Neurosci Lett 2021; 742:135531. 10.1016/j.neulet.2020.135531 CASPubMedWeb of Science®Google Scholar 54Pilotto A, Cristillo V, Cotti Piccinelli S, et al. Long-term neurological manifestations of COVID-19: Prevalence and predictive factors. Neurol Sci 2021; 42(12): 4903–4907. 10.1007/s10072-021-05586-4 PubMedWeb of Science®Google Scholar 55Klein S, Davis F, Berman A, Koti S, D'Angelo J, Kwon N. A case report of coronavirus disease 2019 presenting with tremors and gait disturbance. Clin Pract Cases Emerg Med 2020; 4(3): 324–326. 10.5811/cpcem.2020.5.48023 PubMedGoogle Scholar 56Clark JR, Liotta EM, Reish NJ, et al. Abnormal movements in hospitalized COVID-19 patients: A case series. J Neurol Sci 2021; 423: 117377. 10.1016/j.jns.2021.117377 CASPubMedWeb of Science®Google Scholar 57Ray STJ, Abdel-Mannan O, Sa M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: A prospective national cohort study. Lancet Child Adolesc Health 2021; 5(9): 631–641. 10.1016/S2352-4642(21)00193-0 CASPubMedWeb of Science®Google Scholar 58DeVette CI, Ali CS, Hahn DW, DeLeon SD. Acute rheumatic fever in a COVID-19-positive pediatric patient. Case Rep Pediatr 2021; 2021: 6655330. PubMedGoogle Scholar 59Yüksel MF, Yıldırım M, Bektaş Ö, Şahin S, Teber S. A sydenham chorea attack associated with COVID-19 infection. Brain Behav Immun Health 2021; 13:100222. 10.1016/j.bbih.2021.100222 PubMedGoogle Scholar 60Ghosh R, Dubey S, Roy D, Ray A, Pandit A, Ray BK, Benito-León J. Choreo-ballistic movements heralding COVID-19 induced diabetic ketoacidosis. Diabetes Metab Syndr 2021; 15(3): 913–917. 10.1016/j.dsx.2021.04.010 CASPubMedWeb of Science®Google Scholar 61Cotta Ramusino M, Perini G, Corrao G, Farina L, Berzero G, Ceroni M, Costa A. Sars-Cov-2 in a patient with acute chorea: Innocent bystander or unexpected actor? Mov Disord Clin Pract. 2021; 8(6): 950–953. 10.1002/mdc3.13274 PubMedWeb of Science®Google Scholar 62Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Mov Disord 2020; 35(5): 716–720. 10.1002/mds.28084 CASPubMedWeb of Science®Google Scholar 63von Economo K. Die encephalitis lethargica. Wien Klin Wochenschr 1918; 30: 581–585. Google Scholar 64Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol 2020;92(10):1743–1744. 10.1002/jmv.25826 PubMedWeb of Science®Google Scholar 65Gonzalez-Latapi P, Fearon C, Fasano A, Lang AE. Parkinson's disease and COVID-19: do we need to be more patient? Mov Disord 2021; 36(2): 277. 10.1002/mds.28469 CASPubMedWeb of Science®Google Scholar 66Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol 2021; 20(2): 94–95. 10.1016/S1474-4422(20)30442-7 CASPubMedWeb of Science®Google Scholar 67Snyder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairments in an animal model of parkinsonism. Ann Neurol 1985; 18(5): 544–551. 10.1002/ana.410180506 CASPubMedWeb of Science®Google Scholar 68Méndez-Guerrero A, Laespada-García MI, Gómez-Grande A, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 2020; 95: e2109–e2118. 10.1212/WNL.0000000000010282 CASPubMedWeb of Science®Google Scholar 69Fearon C, Mikulis DJ, Lang AE. Parkinsonism as a sequela of SARS-CoV-2 infection: Pure hypoxic injury or additional COVID-19-related response. Mov Disord. Published online May 27 2021; 36: 1483–1484. 10.1002/mds.28656 CASPubMedWeb of Science®Google Scholar 70Ayele BA, Demissie H, Awraris M, et al. SARS-COV-2 induced parkinsonism: the first case from the sub-Saharan Africa. Clin Park Relat Disord 2021; 5:100116. 10.1016/j.prdoa.2021.100116 PubMedGoogle Scholar 71Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson's disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19(10):804–805. doi:10.1016/S1474-4422(20)30305-7 Google Scholar 72Faber I, Brandão PRP, Menegatti F, de Carvalho Bispo DD, Maluf FB, Cardoso F. Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case. Mov Disord. 2020;35(10):1721–1722. doi:10.1002/mds.28277 Google Scholar 73Akilli NB, Yosunkaya A. Part of the Covid19 puzzle: Acute parkinsonism. Am J Emerg Med. 2021;47:333.e1–333.e3. doi:10.1016/j.ajem.2021.02.050 Google Scholar 74Makhoul K, Jankovic J. Parkinson's disease after COVID-19. J Neurol Sci. 2021;422:117331. doi:10.1016/j.jns.2021.117331 Google Scholar 75Cavallieri F, Fioravanti V, Toschi G, et al. COVID-19 and Parkinson's disease: a casual association or a possible second hit in neurodegeneration?. J Neurol. 2022;269(1):59–61. doi:10.1007/s00415-021-10694-4 Google Scholar 76Morassi M, Palmerini F, Nici S, et al. SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. 2021;268(11):3980–3987. doi:10.1007/s00415-021-10560-3 Google Scholar 77Ong TL, Nor KM, Yusoff Y, Sapuan S. COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia. J Mov Disord. 2022;15(1):89–92. doi:10.14802/jmd.21063 Google Scholar 78Rao AR, Hidayathullah SM, Hegde K, Adhikari P. Parkinsonism: An emerging post COVID sequelae. IDCases. 2022;27:e01388. doi:10.1016/j.idcr.2022.e01388 Google Scholar 79Philippens IHCHM, Böszörményi KP, Wubben JAM, et al. Brain Inflammation and Intracellular α-Synuclein Aggregates in Macaques after SARS-CoV-2 Infection. Viruses. 2022;14(4):776. Published 2022 Apr 8. doi:10.3390/v14040776 Google Scholar 80Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603–605. 10.1001/jama.2020.12603 CASPubMedWeb of Science®Google Scholar 81Delorme C, Paccoud O, Kas A, et al. COVID-19-related encephalopathy: A case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol 2020; 27(12): 2651–2657. 10.1111/ene.14478 CASPubMedWeb of Science®Google Scholar 82Borroni B, Gazzina S, Dono F, et al. Diaphragmatic myoclonus due to SARS-CoV-2 infection. Neurol Sci 2020; 41(12): 3471–3474. 10.1007/s10072-020-04766-y PubMedWeb of Science®Google Scholar 83Shah PB, Desai SD. Opsoclonus myoclonus ataxia syndrome in the setting of COVID-19 infection. Neurology 2021; 96(1): 33. 10.1212/WNL.0000000000010978 CASPubMedWeb of Science®Google Scholar 84Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, et al. Generalized myoclonus in COVID-19. Neurology 2020; 95(6): e767–e772. 10.1212/WNL.0000000000009829 CASPubMedWeb of Science®Google Scholar 85Grimaldi S, Lagarde S, Harle JR, Boucraut J, Guedj E. Autoimmune encephalitis concomitant with SARS-CoV-2 infection: Insight from 18F-FDG PET imaging and neuronal autoantibodies. J Nucl Med 2020; 61: 1726–1729. 10.2967/jnumed.120.249292 CASPubMedWeb of Science®Google Scholar 86Panariello A, Bassetti R, Radice A, et al. Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report. Brain Behav Immun 2020; 87: 179–181. 10.1016/j.bbi.2020.05.054 CASPubMedWeb of Science®Google Scholar 87Kilic MA, Yoruk Yildirim ZN, Oner A, et al. Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome. J Neurol 2021; 268(12): 4492–4494. 10.1007/s00415-021-10614-6 CASPubMedWeb of Science®Google Scholar 88Durovic E, Bien C, Bien CG, Isenmann S. MOG antibody-associated encephalitis secondary to Covid-19: Case report. BMC Neurol 2021; 21(1): 414. 10.1186/s12883-021-02449-5 PubMedWeb of Science®Google Scholar 89Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2021; 2(5):100288. 10.1016/j.xcrm.2021.100288 CASPubMedGoogle Scholar 90Ros-Castelló V, Quereda C, López-Sendón J, Corral I. Post-hypoxic myoclonus after COVID-19 infection recovery. Mov Disord Clin Pract. 2020; 7(8): 983–984. 10.1002/mdc3.13025 PubMedWeb of Science®Google Scholar 91Anand P, Zakaria A, Benameur K, et al. Myoclonus in patients with coronavirus disease 2019: A multicenter case series. Crit Care Med 2020; 48: 1664–1669. 10.1097/CCM.0000000000004570 CASPubMedWeb of Science®Google Scholar 92Mas Serrano M, Pérez-Sánchez JR, Portela Sánchez S, et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. J Neurol Sci 2020; 415:116944. 10.1016/j.jns.2020.116944 CASPubMedWeb of Science®Google Scholar 93Lorant V, Smith P, Van den Broeck K, Nicaise P. Psychological distress associated with the COVID-19 pandemic and suppression measures during the first wave in Belgium. BMC Psychiatry 2021; 21: 112. 10.1186/s12888-021-03109-1 CASPubMedWeb of Science®Google Scholar 94Delgado C, Pareés I, Jiménez-Huete A, Kurtis MM. Impact of the coronavirus disease 2019 pandemic on functional movement disorders: Lessons from a specialized clinic. Mov Disord 2020; 35: 1723–1724. 10.1002/mds.28278 CASPubMedWeb of Science®Google Scholar 95Kanaan RA, Chen G, Olver J. How has the COVID pandemic affected functional neurological disorder? A mixed-methods analysis. Gen Hosp Psychiatry 2021; 69: 129–130. 10.1016/j.genhosppsych.2020.12.014 PubMedWeb of Science®Google Scholar 96Nisticò V, Goeta D, Gambini O, Demartini B. The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders: A preliminary study. Parkinsonism Relat Disord 2020; 78: 79–81. 10.1016/j.parkreldis.2020.07.019 PubMedWeb of Science®Google Scholar 97Di Vico IA, Riello M, Marotta A, et al. The impact of lockdown on functional motor disorders patients during the first COVID-19 outbreak: Acase-control study. Parkinsonism Relat Disord 2021; 93: 40–42. 10.1016/j.parkreldis.2021.11.007 CASPubMedWeb of Science®Google Scholar 98Sandri A, Di Vico IA, Riello M, Marotta A, Tinazzi M. The impact of recurrent Covid-19 waves on patients with functional movement disorders: a follow-up study. Clin Park Relat Disord. 2022; 6:100139. 10.1016/j.prdoa.2022.100139 PubMedGoogle Scholar 99Hull M, Parnes M, Jankovic J. Increased incidence of functional (psychogenic) movement disorders in children and adults amid the COVID-19 pandemic: a cross-sectional study. Neurol Clin Pract 2021; 11(5): e686–e690. 10.1212/CPJ.0000000000001082 PubMedWeb of Science®Google Scholar 100Pringsheim T, Ganos C, McGuire JF, et al. Rapid onset functional tic-like behaviors in young females during the COVID-19 pandemic. Mov Disord 2021; 36(12): 2707–2713. 10.1002/mds.28778 CASPubMedWeb of Science®Google Scholar 101Heyman I, Liang H, Hedderly T. COVID-19 related increase in childhood tics and tic-like attacks. Arch Dis Child 2021; 106(5): 420–421. 10.1136/archdischild-2021-321748 Web of Science®Google Scholar 102Paulus T, Bäumer T, Verrel J, et al. Pandemic tic-like behaviors following social media consumption. Mov Disord 2021; 36(12): 2932–2935. 10.1002/mds.28800 CASPubMedWeb of Science®Google Scholar 103Pringsheim T, Martino D. Rapid onset of functional tic-like behaviours in young adults during the COVID-19 pandemic. Eur J Neurol 2021; 28: 3805–3808. 10.1111/ene.15034 PubMedWeb of Science®Google Scholar 104Hull M, Parnes M. Tics and TikTok: Functional tics spread through social media. Mov Disord Clin Pract 2021; 8(8): 1248–1252. 10.1002/mdc3.13267 PubMedWeb of Science®Google Scholar 105Machado M, Tarrano C, Mesrati F, Roze E, Vidailhet M, Aubignat M. Functional movement disorders during the COVID-19 pandemic: Back to Charcot's era at the Salpêtrière. Mov Disord 2022; 37(2): 432–434. 10.1002/mds.28875 CASPubMedWeb of Science®Google Scholar 106Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study. Lancet Psychiatry 2020; 7(10): 875–882. 10.1016/S2215-0366(20)30287-X PubMedWeb of Science®Google Scholar 107Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 2021; 93(2): 1013–1022. 10.1002/jmv.26368 CASPubMedWeb of Science®Google Scholar 108Garg A, Goyal S, Comellas AP. Post-acute COVID-19 functional movement disorder. SAGE Open Med Case Rep 2021; 9: 2050313X211039377. 10.1177/2050313X211039377 PubMedWeb of Science®Google Scholar 109Fasano A, Daniele A. Functional disorders after COVID-19 vaccine fuel vaccination hesitancy. J Neurol Neurosurg Psychiatry 2022; 93(3): 339–340. 10.1136/jnnp-2021-327000 PubMedWeb of Science®Google Scholar 110Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol Sci 2021; 42(10): 3989–3990. 10.1007/s10072-021-05504-8 PubMedWeb of Science®Google Scholar 111 Immunization stress-related response. A Manual for Program Managers and Health Professionals to Prevent, Identify and Respond to Stressrelated Responses Following Immunization. Geneva: World Health Organization; 2019. Google Scholar 112Taylor S, Asmundson GJG. Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic. J Anxiety Disord 2021; 84:102489. 10.1016/j.janxdis.2021.102489 PubMedWeb of Science®Google Scholar Citing Literature Volume10, IssueS2Supplement: 1st MDCP Conference: Unanswered Questions and Unmet Clinical Needs in Movement Disorders London, United KingdomAugust 2023Pages S9-S17 This article also appears in:MDCP Conference on Unmet Needs & Unanswered Questions in Clinical PracticeSpecial Collection: COVID-19 Resources ReferencesRelatedInformation
Referência(s)